| Turning liabilities into opportunities: Off-target based drug repurposing in cancer V Palve, Y Liao, LLR Rix, U Rix Seminars in cancer biology 68, 209-229, 2021 | 62 | 2021 |
| H2O2/Peroxynitrite-Activated Hydroxamic Acid HDAC Inhibitor Prodrugs Show Antileukemic Activities against AML Cells Y Liao, L Xu, S Ou, H Edwards, D Luedtke, Y Ge, Z Qin ACS medicinal chemistry letters 9 (7), 635-640, 2018 | 45 | 2018 |
| TRK xDFG mutations trigger a sensitivity switch from type I to II kinase inhibitors E Cocco, JE Lee, S Kannan, AM Schram, HH Won, S Shifman, A Kulick, ... Cancer discovery 11 (1), 126-141, 2021 | 41 | 2021 |
| Synthesis and antileukemic activities of piperlongumine and HDAC inhibitor hybrids against acute myeloid leukemia cells Y Liao, X Niu, B Chen, H Edwards, L Xu, C Xie, H Lin, L Polin, JW Taub, ... Journal of medicinal chemistry 59 (17), 7974-7990, 2016 | 37 | 2016 |
| Chemical proteomics with novel fully functionalized fragments and stringent target prioritization identifies the glutathione-dependent isomerase GSTZ1 as a lung cancer target Y Liao, S Chin Chan, EA Welsh, B Fang, L Sun, E Schönbrunn, ... ACS Chemical Biology 18 (2), 251-264, 2023 | 4 | 2023 |
| Differential Chemoproteomics Reveals MARK2/3 as Cell Migration‐Relevant Targets of the ALK Inhibitor Brigatinib Q Hu, Y Liao, J Cao, B Fang, SY Yun, F Kinose, EB Haura, HR Lawrence, ... Chembiochem 24 (11), e202200766, 2023 | 2 | 2023 |
| FDA approved library screen revealed Ewing and clear cell sarcomas have increased sensitivity to filanesib over other cancer types HL Walker-Mimms, N Londono, Y Liao, N Chaudhary, DP Gomez, ... Cancer Research 84 (6_Supplement), 647-647, 2024 | | 2024 |
| Differential network analysis of ROS1 inhibitors reveals lorlatinib polypharmacology through co-targeting PYK2 Y Liao, LLR Rix, X Li, B Fang, V Izumi, EA Welsh, A Monastyrskyi, ... Cell Chemical Biology 31 (2), 284-297. e10, 2024 | | 2024 |
| Does artificial intelligence need companionship to assist in drug discovery? The Kirsten rat sarcoma virus study M Stitou, JM Koomen, DJ Imbody, Y Liao, A Monastyrskyi, U Rix, ... BJR| Artificial Intelligence 1 (1), ubae001, 2024 | | 2024 |
| Discovery of GSTZ1 as a novel target for drug refractory non-small cell lung cancer by using fragment-based chemical proteomics Y Liao, SC Chan, EA Welsh, B Fang, L Sun, E Schönbrunn, JM Koomen, ... Cancer Research 83 (7_Supplement), 3839-3839, 2023 | | 2023 |
| Discovery of GSTZ1 as a novel target by using fully functionalized fragment-like probes and chemical proteomicsDiscovery Y Liao, SC Chan, E Welsh, B Fang, J Koomen, D Duckett, E Haura, ... MOLECULAR & CELLULAR PROTEOMICS 21 (8), S46-S46, 2022 | | 2022 |
| Discovery Of Piperlongumine Derivatives As Anti-Leukemic And Anti-Prostate Cancer Agents Y Liao Wayne State University, 2018 | | 2018 |
